104629-86-9

Basic information

• Product Name: 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER
• Synonyms: 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER;Ethyl5-methoxy-3-oxopentanoate
• CAS NO: 104629-86-9
• Molecular Formula: C₈H₁₄O₄
• Molecular Weight: 174.19
• Mol File: 104629-86-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 230.869°C at 760 mmHg
• Flash Point: 93.382°C
• Appearance: /
• Density: 1.04g/cm³
• Vapor Pressure: 0.064mmHg at 25°C
• Refractive Index: 1.423
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER(104629-86-9)
• EPA Substance Registry System: 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER(104629-86-9)

Safety Data

• Hazardous Substances Data: 104629-86-9(Hazardous Substances Data)

Usage

General Description

5-Methoxy-3-oxo-pentanoic acid ethyl ester is a chemical compound with a molecular formula C8H14O4. It is an ester formed by the condensation of 5-methoxy-3-oxo-pentanoic acid and ethanol. 5-METHOXY-3-OXO-PENTANOIC ACID ETHYL ESTER is commonly used as a flavoring agent and fragrance ingredient in various consumer products. It has a fruity and sweet odor, and is often found in perfumes, soaps, and cosmetics. Additionally, it is also used in the production of pharmaceuticals and as an intermediate in organic synthesis reactions. Overall, 5-methoxy-3-oxo-pentanoic acid ethyl ester has a wide range of applications in the fragrance, cosmetic, and pharmaceutical industries.

InChI:InChI=1/C8H14O4/c1-3-12-8(10)6-7(9)4-5-11-2/h3-6H2,1-2H3

Upstream product

• 110-67-8 3-Methoxypropionitrile 
• 105-36-2 ethyl bromoacetate 
• 2544-06-1 3-Methoxypropionic acid 
• 6148-64-7 ethyl potassium malonate 

Downstream Products

• 774605-37-7 3-(2,6-dichloro-phenyl)-5-(2-methoxy-ethyl)-isoxazole-4-carboxylic acid ethyl ester 
• 1335027-65-0 ethyl 2-[4-fluoro-3-(trifluoromethyl)benzyl]-5-methoxy-3-oxopentanoate 
• 774605-60-6 3-(2,6-dichloro-phenyl)-5-(2-methoxy-ethyl)-isoxazole-4-carboxylic acid 

Relevant articles and documents

4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS

The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical com

Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity

Endothelins, ET-1, ET-2, and ET-3 are potent vasoconstricting and mitogenic 21-amino acid bicyclic peptides, which exert their effects upon binding to the ET(A) and ET(B) receptors. The ET(A) receptor mediates vasoconstriction and smooth muscle cell proliferation, and the ET(B) receptor mediates different effects in different tissues, including nitric oxide release from endothelial cells, and vasoconstriction in certain vascular cell types. Selective antagonists of endothelin receptor subtypes may prove useful in determining the role of endothelin in various tissue types and disease states, and hence as therapeutic agents for such diseases. The pyrrolidine carboxylic acid A-127722 has been disclosed as a potent and ET(A)-selective antagonist, and is currently undergoing clinical trials. In our efforts to find antagonists with altered selectivity (ET(A)-selective, ET(B)-selective, or nonselective), we investigated the SAR of the 2-substituent on the pyrrolidine. Compounds with alkyl groups at the 2-position possessed ET(A) selectivity improved over A-127722 (1400-fold selective), with the best of these compounds showing nearly 19,000-fold selectivity. Copyright (C) 1999 Elsevier Science Ltd.

Porphycene compounds for photodynamic therapy

A porphycene having the structure STR1 wherein each R1 is, independently, (a) --(CH2)n --X, where n=1-4, X is OR2 and R2 is C1-6 alkyl, aralkyl or aryl; CN; OH; OSO2 R2 ; NH2 ; NHR2 ; NR22 ; SH; SR2 ; S(O)1-2 R2 ; COOH; CO2 R2 ; C(O)NH2 ; C(O)NHR2 ; C(O)NR22 ; halogen; or CHO; (b) --(CH2)m CH=CH2 where m is 0-2; or (c) --(CH2)n --O--G where G is a mono- or oligosaccharide; (d) --(CH2)2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH2)n -porphycene2 (porphycene2 being a compound of the same structure and Y is a direct bond; --O--; or --CH=CH2); or (e) where one, two or three of the substituents R1 are C1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof. The porphycene compounds and pharmaceutical compositions containing the compounds are useful in photodynamic therapy treatment of tumors and psoriasis.